Introduction

D
rug utilization patterns are affected by insurance coverage for medicines and levels of patient co-payments. [1] [2] [3] [4] [5] Patients with high out-of-pocket costs for medicines have been observed to use smaller amounts than intended to make the medicine supply last longer. 6 In a recent cross-national study, the prevalence of self-reported cost-related non-adherence ranged from 3 to 20%. 5 The pharmaceutical reimbursement systems differed between the included countries with respect to patients' co-payment, cost ceilings and whether pharmaceutical insurance was universal. The lowest prevalence of cost-related non-adherence was observed in The Netherlands, which was the country with the lowest patient copayments and lowest median annual out-of-pocket costs. 5 A reduction in the use of essential medicines has been observed following increased patient co-payment, which has resulted in higher rates of adverse events. 4 The Swedish Pharmaceutical Benefits Scheme
The Swedish Pharmaceutical Benefits Scheme (PBS) aims to protect individuals from high costs for medicines and has universal coverage. 7 The co-payment at each purchase occasion is based on the price of the purchased medicines and the accumulated copayment for medicines, included in the PBS, that are purchased before and on that occasion. During the study period, the patient co-payment corresponded to the full price of medicines up to an accumulated co-payment corresponding to E104.7 (E1 = Swedish krona 8.60, November 2012). The co-payment corresponds to a proportion of the price that decreases as the accumulated copayment increases; 50% of the price when the accumulated copayment ranged between E104.8 and E151.2, 25% when the accumulated co-payment was between E151.3 and E197.7 and 10% when the accumulated co-payment was between E197.8 and E209.3. Once patients had reached the maximum accumulated copayment, they were exempt from further co-payments for the rest of the 12-month reimbursement period. Private insurances to cover for patient co-payment exist but are uncommon in Sweden.
A previous study from a Swedish county found that individuals who paid co-payments were more likely to have an undersupply of medicines compared with those who were exempt from co-payment. This indicates a possible cost-related non-adherence in the Swedish reimbursement system. 8 Reducing cost-related non-adherence is important both from a medical viewpoint and an equity perspective. Analysing the impact of patients' costs for medicines on adherence in the Swedish setting can therefore contribute with knowledge regarding the sensitivity to out-of-pocket costs to non-adherence. The aim of this study was to analyse how refill adherence in Sweden varies according to level of co-payment for reimbursed medicines, with antiepileptic drug (AED) use as an example. The hypothesis is that adherence for AED will be lowest when patients pay a relatively high cost for their medicines and highest when patients are exempt from co-payment.
AED was chosen as an example for this study because epilepsy is a symptomatic disease where $60% of patients achieve full control of their seizures with AED. 9 Moreover, non-adherence has been associated with an increased risk for seizures, 10 hospitalizations 11, 12 and death. 12 AEDs also include products with both a relatively low price and a relatively high price.
Methods
This study is part of the RARE project (Refill Adherence in Registers). 13 The RARE project has been approved by the regional ethical review board in Gothenburg, Sweden (No. 284-09).
Study population
Patients aged 18-85 years who purchased an AED (Anatomical Therapeutic Chemical classification system code: N03A) on regular prescriptions between 1 January and 30 June 2007 (the index period) were identified in the Swedish Prescribed Drug Register (SPDR) (N = 92 795). The date of the first AED purchase during the index period was defined as the index date for each individual. In this study, prevalent users were included because the AED dosages are likely to be unstable when treatment is initiated, and it would be difficult to estimate the AED dosages with acceptable validity. Patients purchasing multidose dispensed medicines (ApoDos) were not eligible for inclusion, as they generally receive their prescribed medicines automatically from the pharmacy. Further, information on the prescribed daily dose is missing for these individuals. In Sweden, it is possible to purchase 18 months of medicine supply within the PBS during the 12-month reimbursement period. To reduce the effects of stockpiling on the adherence measure, patients were excluded if the index purchase was not the first AED purchase of the reimbursement period. Patients who purchased more than one AED substance were excluded because it was not possible to determine whether the AED substances were intended for combination use or if the patient switched from one AED to another. Further exclusion criteria are presented in figure 1. Individuals were followed until discontinuation of AED treatment, emigration, death or until 2 years after their index date, whichever occurred first. Discontinuation was defined as a gap of at least 90 days with no refills from the assumed end date of the individual's last AED purchase.
Data sources
The data sources have been described in detail elsewhere. 13 Briefly, data on dispensed medicines were collected from the SPDR 14 with information on all dispensed prescriptions irrespective of reimbursement status, but not medicines provided in hospital. Information on hospital admissions, both time in hospital and hospital discharge diagnoses classified according to the International Classification of Diseases, 10th revision (ICD-10), was collected from the National Patient Register. 15 Date of emigration or death and socio-demographic variables were collected from the longitudinal integration database for health insurance and labour market studies. 16 The record linkage was performed by the register holders using the unique person identification number as the identification key. 17 The register holders then de-identified the data.
Estimation of patients' out-of-pocket cost for medicines
The exposure variable was patients' co-payment for all medicines, representing the level of co-payment for the patient in the PBS. Patient time was categorized based on the accumulated copayment for all medicines per reimbursement period following the index purchase. The co-payment categories were based on the copayment levels in the PBS: 100% (E0-104.7), 50% (E104.8-151.2), 25% (E151.3-197.7), 10% (E197.8-209.3) and exempted from copayment (E209.4 or more). Refill adherence to AED treatment was estimated in each of these patient time categories. Elective patient costs outside the PBS were not included, i.e. what patient pays to get the prescribed brand when a cheaper generic is available.
Estimation of refill adherence
The outcome variable was refill adherence estimated with the continuous measure of medication acquisition (CMA). CMA measures the proportion of days' supply obtained during a given period. 18 
CMA ¼
Number of day's supply Number of days in the observation period For each AED purchase, the number of days' supply was estimated based on purchased amount (e.g. 90 tablets) and interpretation of the dosage instruction (e.g. 'Take 1 tablet per day'). Dosage instructions are available as a text string variable in the SPDR. We have previously developed an algorithm to interpret the dosage instructions for statins. 13 For the present study, this algorithm was validated for AED by one of the authors (E.L.) and inaccuracies were corrected. If one dosage instruction was not interpretable, the preceding interpretable dosage instruction was used. If the first dosage instruction or no dosage instructions were interpretable, the patient was excluded (figure 1). Overlaps occurring when a new medicine supply was purchased before the supply from the preceding purchase had theoretically been consumed were added to the subsequent prescription. Refill adherence was used as a categorical variable in the analyses, and patients with a CMA !80% during the entire observation period were considered to be adherent. 
Statistical analyses
Descriptive statistics were used to characterize the sample. Chisquare tests were used to assess differences in categorical variables between adherent individuals (CMA ! 80%) and non-adherent individuals (CMA < 80%), and the Wilcoxon-Mann-Whitney test was used for continuous non-normally distributed variables. The unadjusted association between patients' co-payment for AED and all medicines, respectively, and adherence was assessed with multilevel mixed-effects linear regression, accounting for clustering within patients. 19 Level of accumulated co-payment was modelled as a category variable, and the reference category was 100% copayment (E0-104.7). To identify relevant covariates, the associations between adherence and each covariate were then assessed in separate regression models, always including the co-payment category. All covariates yielding P 0.10 (in at least one of their subcategories) were subsequently included in further regression models. Backward elimination was applied, and covariates with P > 0.05 were dropped from the model. To assess the associations between adherence and each co-payment category, a mixed-model analysis of covariance (ANCOVA) accounting for clustering within individuals was used. The ANCOVA was constructed with a mixedlinear regression model, which accounted for clustering within individuals. The P-values were corrected for multiple comparisons with the Holm-Bonferroni method. 20 The same covariates were included as in the final regression models described above. All statistical analyses were performed using Stata version 10.1.
Results
The final study population included 2210 patients, with a mean (median) follow-up time of 1.8 (2.0) years. The mean (median) age at index was 56 (58) years, and 54% were men (table 1). The median [interquartile range (IQR)] CMA was 95.6% (86.2-99.7%). Applying an 80% cut-off for CMA, 83% were categorized as adherent. Differences for adherent patients compared with the non-adherent patients were observed in age, marital status, income, use of social or unemployment benefits and AED substances used (table 1) .
Co-payment for all medicines
Refill adherence to AED was higher when the patients had a lower level of co-payment for all medicines ( 50%, !E0-104.8) compared with patients with 100% co-payment (E0-104.7) (table 2). After backward elimination (excluding marital status), the final multilevel mixed-effects linear regression showed that the CMA was 91% for patients with 100% co-payment (up to E104.7). Refill adherence to AED was 2-4% higher for patients with a copayment of 50% (E104.8 or more) compared with patients with a 100% co-payment (E104.7). Adherence was higher for patients aged !65 years compared with patients aged between 30 and 49 years, for patients in income Q3 and Q5 compared with patients in income Q1 (lowest income) and for patients on fenytoin compared with those on carbamazepine (table 2). The intracluster correlation coefficient in the final model was 0.269. In the ANCOVA model, 2-4% higher adherence for AED was observed for patients with a co-payment of 50% (at least E104.8) compared with a 100% co-payment (<E104.7) (table 3 ). An increased adherence of 2-4% was observed for patients who were exempted from co-payment (!E209.4) compared with those with a co-payment of !25% ( E197.7). However, no difference in adherence to AED was observed in patients with a co-payment of 10% (E197.8 and E209.3) or when the patients were exempt from co-payment (!E209.4).
Discussion
Accounting for patients' co-payment for all medicines, we found that patients with lower co-payment levels for all medicines (the co-payment categories of 50%) had a statistically significant higher adherence to AED of 2-4 % compared with patients with no reduction in co-payment (the co-payment category of 100% copayment). There was, however, no difference in adherence to AED in patients with a 10% co-payment for all medicines or patients exempted from co-payment. Although the reimbursement systems differ by country, a negative association with co-payment and adherence has also been observed elsewhere.
2,4,11 21 In a recent literature review on whether patients' out-of-pocket costs affected adherence and other outcomes, 85% of the included articles found a statistically significant relationship between increased patient costsharing and decreased adherence. 21 Based on this, it was estimated that for each dollar increase in co-payment, a 0.4% decrease in adherence would be expected.
Even though we found a negative association between co-payment and refill adherence in this study, refill adherence for AED is relatively high in Sweden compared with other countries. In this study, 83% of the included patients were defined as adherent to AED, compared with previous studies where 36-71% of patients using AED were estimated to be adherent. 11, [22] [23] [24] [25] One reason for the relatively high levels of adherence in our study could be that the negative effects of co-payment are reduced for each level of decreased co-payment as was observed in this study. An annual maximum accumulated co-payment has also been observed to decrease the negative effects of co-payment on adherence by others. 5, 26 The Swedish co-payment levels within PBS were increased in January 2012; the annual maximum co-payment is now E255.8. 7 Because of the negative association of co-payment and adherence, 2, 4, 11, 21 this change may affect adherence in Sweden negatively. Previous policy changes in Sweden, with similar content, have only had temporary effects of the volume sold. 27 This maximum accumulated co-payment can also be compared with the annual costs of medicines reported in a seven-country survey. 5 Participants in Canada, The Netherlands, the UK and the USA reporting annual costs of USD 100-499, corresponding to E77-385, were two to three times more likely to report cost-related non-adherence compared with those with annual costs of USD 99 (E76).
Patients use different strategies to cope with cost-related nonadherence, e.g. stop taking medications, split pills, delay refills, skip doses and avoid new prescriptions. 28 When experiencing costrelated non-adherence, patients may choose to stop taking certain medicines and continue another treatment. 28 The patients may, however, not have the information needed to make wise decisions about necessary treatment, thus not fully understanding the potential consequences of cost-related non-adherence. 4, 28 Much debated in the USA is a value-based insurance design, which can be used to help patients make the right decisions. 29 This insurance design recognizes patient-related factors and the value of clinical interventions in health care. Patients are encouraged to use services with strong scientific evidence of clinical benefit, instead of those with low value, by financial incentives. An American retrospective cohort study including almost 75 000 individuals found an association between value-based insurance design and improved adherence, especially for those who were non-adherent to start with. 30 Cost-related non-adherence has been reported to cause adverse events, 4 emergency room visits 4 and an overall decline in self-reported health status. 31 In three register-based US studies [10] [11] [12] focusing on AED, an increased risk of seizures, 10 an increased likelihood of hospitalization, 11 an increased likelihood of emergency room admissions 11 and an increased risk of mortality 12 were reported among non-adherent patients compared with adherent patients. It is therefore of great importance to take the risk associated with cost-related non-adherence into account when considering increasing patient co-payments.
Strengths and limitations
The major strength of this study is the use of nation-wide register data with information from several registers. The treatment periods in this study were based on the written instructions to the patients on each prescription, which is included in the SPDR, instead of a more technical measure such as defined daily doses. This also allowed variations over time for the included patients. There is no information on medicine use during hospitalization available in the SPDR. By linking the SPDR to the patient register we could avoid misclassification of time with no refilled prescriptions due to the patient being hospitalized. Moreover, we used the information in the patient register to exclude patients without an epilepsy diagnosis because AEDs also are used for indications besides epilepsy, e.g. bipolar disease and pain. The SPDR was also linked to other registers to control for factors like socio-demographic characteristics that might affect cost-related non-adherence. It was, however, not possible to evaluate whether patients saved on other basic needs to afford filling their prescriptions. One limitation of this study was that patients not filling any prescription at all owing to costs would not have been registered in the SPDR and thus would not have been included in our analyses. It is therefore possible that cost-related non-adherence could have been underestimated. However, because we included patients with a diagnosis of epilepsy, where the symptoms for the disease include seizures, we consider it to be unlikely that an underestimation would have had a large impact on the results. An explorative approach was used to define the final regression model, which was specified by backward selection of variables. The study end points were estimated using the same data set as for model specification. Compared with a pre-specified model or a split sample design, the use of this approach is a limitation of the study design.
In conclusion, we found that adherence to AEDs in Sweden is relatively high, with >80% of patients considered adherent. Refill adherence for AEDs was higher when the co-payment corresponded to 50% of the price compared with co-payment of 100% of the price for all drugs. In Sweden, co-payment is reduced in a stepwise manner, and one reason for the relatively high levels of adherence to AEDs in Sweden could be that the negative effects of co-payment are reduced for each level of decreased co-payment. It is important to take into account risks of cost-related non-adherence when making policy changes that increase patients' co-payment. 
